Chronic obstructive pulmonary disease • 6: The aetiology of exacerbations of chronic obstructive pulmonary disease

Thorax

Volumn 58, Issue 1, 2003, Pages 73-80

  White, A J ^a   Gompertz, S ^a   Stockley, R A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AIR POLLUTION; AIR QUALITY; ANTIBIOTIC RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; GENETIC SUSCEPTIBILITY; HUMAN; LUNG FUNCTION; LUNG VENTILATION PERFUSION RATIO; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AIR POLLUTION; AIRWAY OBSTRUCTION; BACTERIAL INFECTIONS; DISEASE SUSCEPTIBILITY; HUMANS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTILATION-PERFUSION RATIO; VIRUS DISEASES;

EID: 0037260438     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.1.73     Document Type: Review

References (128)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-8.
2. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001;117:1638-45.
3. Garcia-Aymerich J, Monso E, Marrades M, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation: Efram study. Am J Respir Crit Care Med 2001;164:1002-7.
4. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
5. Kanner RE, Renzetti AD Jr, Klauber MR, et al. Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med 1979;67:44-50.
6. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Results from the lung health study. Am J Respir Crit Care Med 2001;164:358-64.
7. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987;317:1309-14.
8. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635-42.
9. Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax 2000;55:631-2.
10. Fisher M, Akhtar AJ, Calder MA, et al. Pilot study of factors associated with exacerbations in chronic bronchitis. BMJ 1969;4:187-92.
11. COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-28.
12. Pauwels R, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease disease: NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
13. Rodriguez-Roisin R. Towards a concensus definition for COPD exacerbations. Chest 2000;117:398-401S.
14. Mossberg B, Afzelius B, Camner P. Mucociliary clearance in obstructive lung diseases. Correlations to the immotile cilia syndrome. Eur J Respir Dis Suppl 1986;146:295-301.
15. Wilson R, Roberts D, Cole P. Effects of bacterial products on human ciliary function in vitro. Thorax 1984;40:125-31.
16. Kubiet M, Ramphal R. Adhesion of nontypeable Haemophilus influenzae from blood and sputum to human tracheobronchial mucins and lactoferrin. Infect Immun 1995;63:899-902.
17. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;9:1333-8.
18. Stockley RA. Cellular mechanisms in the pathogenesis of COPD. Eur Respir J 1996;39:264-9.
19. Tomee JFC, Koeter GH, Hiemstra PS, et al. Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax 1998;53:114-6.
20. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
21. Taylor DC, Cripps AW, Clancy RL. A possible role for lysozyme in determining acute exacerbation in chronic bronchitis. Clin Exp Immunol 1995;102:406-16.
22. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
23. Bresser P, Out TA, van Alphen L, et al. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:947-52.
24. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-85.
25. Hill AT, Bayley D, Campbell EJ, et al. Airways inflammation in chronic bronchitis: the effects of smoking and alpha-1 antitrypsin deficiency. Eur Respir J 2000;15:886-90.
26. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
27. Gompertz S, O'Brien C, Bayley D, et al. Comparison of stable state bronchial inflammation in chronic bronchitis and previously unsuspected bronchiectasis. Eur Respir J 1999;14:165S.
28. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-11.
29. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
30. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
31. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis: characterisation and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
32. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-7.
33. Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001;56:366-72.
34. Lacoste J-Y, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-48.
35. O'Connel JM, Baird LI, Campbell AH. Sputum eosinophilia in chronic bronchitis and asthma. Respiration 1978;35:65-72.
36. Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998;12:380-6.
37. Aaron S, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-55.
38. Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-80.
39. Gompertz S, O'Brien C, Bayley D, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-9.
40. 1-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160:1968-75.
41. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56:30-5.
42. Sethi S, Muscarella BS, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-65.
43. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-5.
44. Zhu J, Qiu YS, Majumdar S, et al. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001;164:109-16.
45. Bone RC. The sepsis syndrome. Definition and general approach to management. Clin Chest Med 1996;17:175-81.
46. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608-13.
47. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60.
48. Smith CB, Kanner RE, Golden CA, et al. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980;141:271-80.
49. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
50. Fernandez A, Lazaro A, Garcia A, et al. Bronchodilators in patients with chronic obstructive pulmonary disease on mechanical ventilation. Utilization of metered-dose inhalers. Am Rev Respir Dis 1990;141:164-8.
51. Lloberes P, Ramis L, Montserrat JM, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988;1:536-9.
52. 2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database Syst Rev 2001;2:CD002984.
53. Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-7.
54. Patrick DM, Dales RE, Stark RM, et al. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;98:295-7.
55. Chalmers GW, Macleod KJ, Sririam S, et al. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur Respir J 1999;13:1288-92.
56. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-7.
57. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in the peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
58. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4.
59. Marchioni CF, Polu JM, Taytard A, et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther 1995;33:612-8.
60. Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997;10:1285-91.
61. Rodriguez-Roisin R. Pulmonary gas exchange in acute respiratory failure. Eur J Anaesthesiol 1994;11:5-13.
62. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
63. Fiorini G, Crespi S, Rinaldi M, et al. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 2000;54:274-8.
64. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1995;26:766-74.
65. Gompertz S, Stockley RA. Inflammation: role of the neutrophil and the eosinophil. Semin Respir Infect 2000;15:14-23.
66. Chanez P, Vignola AM, O'Shaughnessy TC, et al. Corticosteroid reversibilty in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34.
67. Fujimoto K, Kubo K, Yamamoto H, et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999;115:697-702.
68. Burge PS, Calverley PM, Jones PW, et al. Randomised double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
69. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-50.
70. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax 1984;39:663-7.
71. Nadel JA. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000;17:386-9S.
72. May JR. The bacteriology of chronic bronchitis. Lancet 1953;2:534-7.
73. Cabello H, Torres A, Celis R, et al. Distal airway bacterial colonisation in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997;10:1137-44.
74. Monso E, Ruiz J, Manterola J, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
75. Monso E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999;13:338-42.
76. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
77. Adler KB, Hendley DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 1986;125:501-14.
78. Wilson R, Roberts D, Cole P. Effects of bacterial products on human ciliary function in vitro. Thorax 1984;40:125-31.
79. Read RC, Wilson R, Rutman A, et al. Interaction of nontypeable Haemophilus influenzae with human respiratory mucosa in vitro. J Infect Dis 1991;163:549-58.
80. Khair OA, Devalia JL, Abdelaziz MM, et al. Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL- 8, TNF-alpha and expression of ICAM-1 in cultured human bronchial epithelial cells. Eur Respir J 1994;7:2109-16.
81. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
82. Hirschman JV. Do bacteria cause exacerbations of COPD. Chest 2000;118:193-203.
83. Scott KW. Bacteriology of the sputum in exacerbation and remission of chronic bronchitis. Br J Dis Chest 1973;67:43-8.
84. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113:465-74.
85. Murphy TF, Sethi S, Klingman KL, et al. Simultaneous respiratory tract colonisation by multiple strains of nontypeable Haemophylus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999;180:404-9.
86. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990;142:1004-8.
87. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
88. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
89. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-6.
90. Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997;176:1247-52.
91. Chapman A, Musher DM, Jonsson S, et al. Development of bacteriacidal antibody during Branhamella catarrhalis infection. J Infect Dis 1985;151:878-82.
92. Mitchell J, Hill SL. Immune response to Haemophilus parainfluenzae in patients with chronic obstructive lung disease. Clin Diagn Lab Immunol 1999;7:25-30.
93. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
94. Sachs AP, Koeter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-63.
95. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
96. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
97. Woolhouse I, Hill SL, Stockley RA. Symptom resolution assessed using a patient directed diary card during exacerbations of chronic bronchitis. Thorax 2001;56:947-53.
98. Hegele RG, Hayashi S, Hogg JC, et al. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995;151:1659-64.
99. Melbye H, Kongerud J, Vorland L. Reversible airflow limitation in adults with respiratory infection. Eur Respir J 1994;7:1239-45.
100. Jacoby DB, Fryer AD. Interaction of viral infections with muscarinic receptors. Clin Exp Immunol 1999;29:59-64.
101. Buscho RO, Saxtan D, Shultz PS, et al. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978;137:377-83.
102. Carilli AD, Gohd RS, Gordon W. A virological study of chronic bronchitis. N Engl J Med 1964;270:123.
103. Lamy ME, Pouthier-Simon F, Debacker-Willame E. Respiratory viral infections in hospital patients with chronic bronchitis. Observations during periods of exacerbation and quiescence. Chest 1973;63:336-41.
104. Smith CB, Golden CA, Kanner RE, et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980;121:225-32.
105. Stenhouse AC. Viral antibody levels and clinical status in acute exacerbations of chronic bronchitis: a controlled prospective study. BMJ 1968;3:287-90.
106. Seemungal TA, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-83.
107. Smith CB, Golden C, Klauber MR, et al. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976;134:552-61.
108. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;CD002733.
109. Monto AS, Bryan ER. Susceptibility to rhinovirus infection in chronic bronchitis. Am Rev Respir Dis 1978;118:1101-3.
110. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73.
111. Beaty CD, Grayston JT, Wang SP, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev. Respir Dis 1991;144:1408-10.
112. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999;160:349-53.
113. Verkooyen RP, Van Lent NA, Mousavi Joulandan SA, et al. Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA. J Med Microbiol 1997;46:959-64.
114. Lieberman D, Lieberman D, Ben Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis 2001;40:95-102.
115. Karnak D, Beng Sun S, Beder S, et al. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med 2001;95:811-6.
116. Nordenhall C, Pourazar J, Blomberg A, et al. Airway inflammation following exposure to diesel exhaust: a study of time kinetics using induced sputum. Eur Respir J 2000;15:1046-51.
117. Rudell B, Blomberg A, Helleday R, et al. Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particle trap filtered exhaust. Occup Environ Med 1999;56:527-34.
118. Ohtoshi T, Takizawa H, Okazaki H, et al. Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin. Immunol 1998;101:778-85.
119. Kopp MV, Ulmer C, Ihorst G, et al. Upper airway inflammation in children exposed to ambient ozone and potential signs of adaptation. Eur Respir J 1999;14:854-61.
120. Devalia JL, Rusznak C, Herdman MJ, et al. Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. Lancet 1994;344:1668-71.
121. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997;10:1064-71.
122. Garcia-Aymerich J, Tobias A, Anto JM, et al. Air pollution and mortality in a cohort of patients with chronic obstructive pulmonary disease: a time series analysis. J Epidemiol Community Health 2000;54:73-4.
123. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. Am J Respir Crit Care Med 1994;150:648-55.
124. Schwartz J. PM10, ozone, and hospital admissions for the elderly in Minneapolis-St Paul, Minnesota. Arch Environ Health 1994;49:366-74.
125. Sunyer J, Saez M, Murillo C, et al. Air pollution and emergency room admission for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993;137:701-5.
126. Sunyer J, Schwartz J, Tobias A, et al. Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis. Am J Epidemiol 2000;151:50-6.
127. Davies L, Hadcroft J, Mutton K, et al. Antimicrobial management of acute exacerbations of chronic airflow limitation. Q J Med 2001;94:373-8.
128. Smith JA, Redman P, Woodhead MA. Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999;13:835-8.